武汉费斯德生物科技有限公司, NewEast Biosciences 中国办事处
武汉费斯德生物科技有限公司是美国NewEast Biosciences在中国的办事处。NewEast Biosciences 在十二年前率先研发俩种独特的抗体。这俩种抗体仅仅识别活性的GTP酶或者突变的Oncogene。 GTP酶涉及(1)响应细胞表面受体激活的信号转导,包括跨膜受体,例如介导味觉、嗅觉和视觉的那些,(2)核糖体的蛋白质生物合成,(3)调节细胞分化、增殖、分裂和运动,(4)蛋白质通过膜的易位,(5)细胞内囊泡的运输,以及囊泡介导的分泌和摄取,通过GTP酶控制囊泡外壳组装。Oncogene侧是诱发癌症的基因。
我公司将向你提供以下的独一无二的三种抗体或者试剂盒: (1) 仅识别 GTP酶的活性构型的产品, 它可以让你能够量化GTP酶在细胞中的活性和分布。(2) 识别突变 Oncogene蛋白, 但不认识相应野生型的抗体。 (3) 对 cAMP 和 cGMP 具有超亲和力(无需乙酰化)ELISA检测试剂盒。这些产品被将近一千篇同行评议的文章所引用。
¥2,850.00
货号: S218145 | ||||
产品全名: MIOX 兔多抗 | ||||
基因符号 ALDRL6 | ||||
UNIPROT ID: Q9UGB7 (Gene Accession – BC012025 ) | ||||
背景: Myo-inositol oxygenase (MIOX), also known as ALDRL6, is a renal-specific member of the Aldo-keto reductase family. It catalyzes the first committed step in the Myo-inositol metabolism pathway and is widely distributed in mammalian tissues. Human Myo-inositol oxygenase shares 91% and 96% sequence homology with mouse and pig Myo-inositol oxygenase homologs, respectively. Myo-inositol oxygenase is responsible for the oxidative cleavage of Myo-inositol (MI) and its epimer D-chiro inositol (DCI) to D-glucuronate. The dioxygen-dependent cleavage of the C1-C6 bond in Myo-inositol is accomplished through the utilization of the Fe(II)/Fe(III) binuclear iron center of MIOX. Myo-inositol oxygenase has also been implicated in complications of diabetes, including diabetic nephropathy. | ||||
抗原: Full length fusion 蛋白 | ||||
经过测试的应用: ELISA, IHC | ||||
推荐稀释比: IHC: 20-100; ELISA: 5000-10000 | ||||
种属反应性: Rabbit | ||||
克隆性: Rabbit Polyclonal | ||||
亚型: Immunogen-specific rabbit IgG | ||||
纯化: Antigen affinity purification | ||||
种属反应性: Human | ||||
成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol | ||||
研究领域: Metabolism | ||||
储存和运输: Store at -20°C. Avoid repeated freezing and thawing | ||||
|